Figure 4.

ImmunoPET demonstrates the MUC16-dependent uptake of [⁸⁹Zr]Zr-DFO-muAR9.6 in xenograft models of pancreatic ductal adenocarcinoma (PDAC). A, Graph showing the differential binding of 3 ng of [⁸⁹Zr]Zr-DFO-muAR9.6 to five PDAC cell lines expressing different levels of MUC16. B, PET images of mice bearing subcutaneous PDAC xenografts acquired 6 days after the administration of 2.1 ± 0.4 mg/kg of [⁸⁹Zr]Zr-DFO-muAR9.6 (225 ± 22.1 μCi; 8.3 ± 0.8 MBq; 51.7 ± 9.8 μg). C,Ex vivo biodistribution data acquired from mice bearing subcutaneous PDAC xenografts 6 days after the intravenous injection of 0.3 ± 0.03 mg/kg [⁸⁹Zr]Zr-DFO-muAR9.6 (27.7 ± 0.9 μCi; 1.02 ± 0.03 MBq; 6.3 ± 0.8 μg; n = 4 mice per time point). On the graph, *, P ≤ 0.05. Detailed %ID/g values are provided in Supplementary Table S6. D, Representative bioluminescence (BLI) and PET images of female nude mice acquired 4 weeks after the surgical implantation of Luc-Capan-2 cells in the head of the pancreas. The immunoPET images were acquired 6 days after the administration of 1.57 mg/kg of [⁸⁹Zr]Zr-DFO-muAR9.6 (269.4 ± 5.4 μCi; 9.97 ± 0.2 MBq; 40 μg). The maximum intensity projections have been scaled from 0% to 100%.